Guardant Health Reports Q3 Revenue of $361 Million, Raises 2026 Guidance
Third-quarter 2026 revenue was $361.0 million versus FactSet consensus of $350.7 million. Adjusted loss was $0.29 per share versus an expected $0.31 loss; non-GAAP gross margin was 67%. Guardant raised full-year revenue guidance to $1.36 billion-$1.37 billion.
Guardant Health, Inc. announced its financial results for the third quarter of 2026, reporting revenue of $361.0 million, which surpassed the FactSet consensus estimate of $350.7 million. The company achieved an adjusted loss of $0.29 per share, performing better than the anticipated $0.31 per share loss. Driven by strong performance in its oncology and Shield screening volumes, the company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion.
Additionally, the company reported a non-GAAP gross margin of 67% for the period.